TMCnet News

TheSUBWAY.com Inc.: Stock Developments for Tuesday, September 16, 2008: PSTI Promising Results!
[September 16, 2008]

TheSUBWAY.com Inc.: Stock Developments for Tuesday, September 16, 2008: PSTI Promising Results!


(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:16092008

TheSUBWAY.com: Names the following stocks to its Stock Alerts List:
Pluristem Therapeutics Inc. (Nasdaq: PSTI), United Airlines (Nasdaq:
UAUA), Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), Broadcom
Corporation (Nasdaq: BRCM), Altera Corporation (NASDAQ:ALTR), Amgen
(NASDAQ:AMGN).

Visit TheSUBWAY's Small Cap Investor Forum Here:
http://investor-forum.thesubway.com/

Pluristem Therapeutics Inc. (Nasdaq: PSTI), announced today the
successful conclusion of its pre-clinical efficacy studies utilizing
PLX-PAD prior to the initiation of human clinical trials. PLX-PAD is
Pluristem's cellular product for the treatment of critical limb
ischemia (CLI), the end stage of Peripheral Artery Disease (PAD).

Zami Aberman, Pluristem's President and CEO commented, "These final
PLX-PAD efficacy studies show impressive new vessel formation and may
bring hope to millions of people suffering from complications of
diabetes, Buerger's Disease and smoking where insufficient blood flow
to their lower legs places them at risk of amputation. The successful
completion of the PLX-PAD pre-clinical efficacy trials, in accordance
with the regulatory authority's requirements, validates the results we
obtained in our previous studies with this product and gives us
assurances that allogeneic adherent stromal cells will be efficacious
for this disorder. This was our final pre-clinical efficacy study using
PLX-PAD and we now intend to commence human trials, following receipt
of the necessary regulatory approvals."

Technical analysts believe a narrowing of the Bollinger Bands around a
Company's stock price suggests a significant movement will soon occur.
With PSTI, the bands could not be any narrower. The last two times they
approached this level, the stock saw an upswing of over 216% and 60% in
share price.

Other stocks highlighted include:

United Airlines (Nasdaq: UAUA), up 9% on 23 million shares, Monday said
that in a challenging economic environment where fuel prices continue
to be volatile and are more than 50 percent higher than last year,
United is increasing the service fee to check a second bag on a
domestic flight from $25 to $50 one way. These changes apply to
customers who purchase a ticket on or after Sept. 16, 2008, for travel
within the U.S. and to/from Canada, Puerto Rico and the U.S. Virgin
Islands on or after Nov. 10, 2008.

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), down 2% on 10
million shares, Monday announced presentations of several new studies
at the World Congress on Treatment and Research in Multiple Sclerosis
in Montreal. New data will be presented on COPAXONE (glatiramer acetate
injection), a leading therapy for relapsing-remitting multiple
sclerosis (RRMS) treatment, covering early treatment with COPAXONE ,
long-term efficacy and safety.

Broadcom Corporation (Nasdaq: BRCM), down 3% on 13 million shares, a
global leader in semiconductors for wired and wireless communications,
Monday announced its next generation of digital television (DTV)
system-on-a chip (SoC) solutions that bring advanced functionality and
differentiated features to DTV designs to address the U.S. market.
Featuring expandable entry-level to high-end design capabilities, the
new SoC solutions enable TV manufacturers to enhance the DTV from a
commodity display device to a highly differentiated, connected
entertainment system. Included in each of these single-chip solutions
are an advanced multi-format decoder, Ethernet network connectivity, a
3D graphical user interface, and unique 3D color management, all of
which continue to position the TV as the central entertainment
appliance for the digital home.

Altera Corporation (NASDAQ:ALTR), down 3% on 8 million shares, Monday
announced the availability of a 10-gigabit Ethernet (10GbE) reference
design targeting designers using the XAUI communications protocol. Line
cards and system controllers used within network routers, enterprise
and metro Ethernet switches, and storage switches can leverage Altera's
Arria and Stratix series of FPGAs to connect reliably to 10GbE
backplanes or networks. Altera's 10GbE solution is IEEE 802.3ae
standard compliant and successfully passed the University of New
Hampshire Interoperability Lab (UNH-IOL) 10GbE tests.

Amgen (NASDAQ:AMGN), down 1% on 14 million shares, and Biovitrum AB
announced Monday that they have entered into an agreement under which
Biovitrum will acquire the marketed biologic therapeutic products
Kepivance (palifermin) and Stemgen (ancestim) from Amgen, and will also
obtain from Amgen a worldwide exclusive license to Kineret (anakinra)
for its current approved indication. The agreement includes an
inventory of the three products at an undisclosed value. Kineret,
Kepivance and Stemgen generated combined sales of nearly $70 million in
2007.

ABOUT TheSUBWAY.com:


TheSUBWAY.com, a leader in corporate communications and finance,
provides all investors with a wide-ranging set of financial tools,
including original stock market commentary, stock quotes, interactive
charts, portfolio watch, live chat and message boards, etc., plus the
latest news, press releases, investment opinions, and research reports
for all companies highlighted on the site. For more daily commentary,
go to http://www.thesubway.com

TheSubway.com is consistently ranked in the top 4 on the
StockPromoters.com "Best performing promoters of all time" list. This
is out of over 1,000 promoters and promotional campaigns tracked by
StockPromoters.com. Visit http://www.StockPromoters.com for more
details.

All material herein was prepared by CRG Partners, Inc. (CRGP) based
upon information believed to be reliable. The information contained
herein is not guaranteed by CRGP to be accurate, and should not be
considered to be all-inclusive. The companies that are discussed in
this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and
uncertainties. This material is for informational purposes only and
should not be construed as an offer or solicitation of an offer to buy
or sell securities. CRGP is not a licensed broker, broker dealer,
market maker, investment banker, investment advisor, analyst or
underwriter. Please consult a broker before purchasing or selling any
securities viewed on http://www.thesubway.com or mentioned herein. CRGP
has been compensated forty thousand shares for PSTI. CRGP intends to
sell its shares. CRGP and its web site are operated under a license
from Capital Research Group, Inc., TheSUBWAY.com Inc. and One Source
Solutions Inc. (Licensors) and CRGP is not the agent of any of the
Licensors and CRGP is solely responsible for all statements made
herein. CRGP's affiliates, officers, directors and employees intend to
buy and sell additional shares in any company mentioned herein and may
profit in the event those shares rise in value. CRGP will not advise as
to when it decides to sell and does not and will not offer any opinion
as to when others should sell; each investor must make that decision
based on his or her judgment of the market.

CONTACT: Joe Farrar, President, CRG Partners, Inc
Tel: +1 973 332 1366
WWW: http://www.TheSUBWAY.com

((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
[email protected])).

Copyright ? 2008 M2 Communications Ltd.

[ Back To TMCnet.com's Homepage ]